By Counterforce Health Team in Cerezyme (imiglucerase) —

How to Get Cerezyme (Imiglucerase) Covered by Aetna CVS Health in Illinois: Complete Guide to Prior Authorization and Appeals

Quick Answer: Cerezyme requires prior authorization from Aetna CVS Health and is subject to step therapy (Elelyso preferred first). To get coverage: 1) Confirm Gaucher disease diagnosis with enzyme/genetic testing, 2) Document Elelyso trial/failure or contraindication, 3) Submit PA via provider portal with specialist support. If denied, Illinois offers strong appeal rights including automatic external review for medical necessity denials. Start with your prescribing physician today.

Table of Contents

  1. Understanding Your Coverage
  2. Prior Authorization Requirements
  3. Step-by-Step: Fastest Path to Approval
  4. Common Denial Reasons & How to Fix Them
  5. Appeals Playbook for Illinois
  6. Medical Necessity Letter Checklist
  7. Cost-Saving Options
  8. When to Escalate
  9. Frequently Asked Questions

Understanding Your Coverage

Cerezyme (imiglucerase) is a specialty enzyme replacement therapy for Type 1 Gaucher disease that requires careful navigation of Aetna CVS Health's coverage policies. The medication costs approximately $1,700+ per 400-unit vial, making insurance approval essential for most patients.

Coverage at a Glance

Requirement What It Means Where to Find It Source
Prior Authorization Required for all prescriptions Aetna Precertification List Aetna
Step Therapy Elelyso must be tried first Drug formulary guide Aetna
Specialist Required Hematologist or Gaucher expert FDA prescribing information FDA
Diagnosis Confirmation Enzyme assay or genetic testing Clinical policy Aetna
Appeal Deadline 180 days from denial Member handbook Aetna

Prior Authorization Requirements

Aetna CVS Health requires prior authorization for all Cerezyme prescriptions, with specific documentation requirements:

Essential Documentation:

  • Confirmed Type 1 Gaucher disease diagnosis via β-glucosidase enzyme assay (activity <15% of normal) or genetic testing showing GBA gene mutations
  • Prescribing physician must be experienced in Gaucher disease management (typically hematologist or metabolic specialist)
  • Clinical manifestations requiring treatment (anemia, thrombocytopenia, bone disease, hepatomegaly, or splenomegaly)
  • Documentation of Elelyso trial and failure/intolerance, or medical contraindication to Elelyso

Step Therapy Requirements: Aetna's 2024 policy designates Elelyso (taliglucerase alfa) as the preferred enzyme replacement therapy. To obtain Cerezyme coverage, you must document:

  • Previous trial of Elelyso with inadequate response or intolerance
  • Medical contraindication to Elelyso
  • Risk to stable patients if switched from Cerezyme

Step-by-Step: Fastest Path to Approval

1. Confirm Specialist Care (Patient + Clinic) Contact a hematologist or Gaucher disease specialist. Cerezyme requires supervision by a provider experienced in managing infusion reactions and Gaucher disease.

2. Gather Diagnostic Evidence (Clinic) Ensure medical records include β-glucosidase enzyme activity results or genetic testing confirming GBA mutations. Submit via Aetna's Cerezyme precertification form.

3. Document Step Therapy (Clinic) If you haven't tried Elelyso, document medical reasons why it's contraindicated or inappropriate. If you have tried it, include detailed records of inadequate response or adverse effects.

4. Submit Prior Authorization (Clinic) Submit via Aetna provider portal or fax to 1-888-267-3277. Include complete clinical history, current lab values, and treatment goals.

5. Track Decision (Patient + Clinic) Standard decisions: up to 72 hours. Urgent requests: 24-72 hours. Monitor via provider portal or call 1-866-752-7021.

6. Prepare for Potential Denial (Patient + Clinic) Gather additional evidence including peer-reviewed studies, FDA labeling, and specialist letters supporting medical necessity.

7. File Appeal if Denied (Patient + Clinic) Submit within 180 days using Aetna's appeal process, requesting peer-to-peer review and providing comprehensive medical justification.

From our advocates: We've seen the strongest approvals when clinics submit complete packages upfront—diagnosis confirmation, specialist involvement, and clear documentation of why Cerezyme specifically is medically necessary. Don't assume the reviewer knows Gaucher disease; spell out the clinical rationale clearly.

Common Denial Reasons & How to Fix Them

Denial Reason How to Overturn Required Documentation
"Not medically necessary" Submit detailed clinical rationale with specialist letter Treatment goals, disease progression, lab values
"Step therapy not met" Document Elelyso trial/failure or contraindication Prior therapy records, adverse event documentation
"Non-formulary" Request formulary exception with medical necessity FDA indication, guideline support, specialist recommendation
"Experimental/investigational" Cite FDA approval and established guidelines FDA label, peer-reviewed studies, treatment protocols
"Dosing outside guidelines" Justify individualized dosing with clinical evidence Weight-based calculations, response monitoring, specialist rationale

Appeals Playbook for Illinois

Illinois offers exceptionally strong patient rights for insurance appeals, with recent 2025 amendments strengthening the process significantly.

Internal Appeal Process:

  • Deadline: 180 days from denial date
  • Decision timeline: 15 business days (expedited: 24 hours)
  • Submission: Via Aetna provider portal or mail/fax
  • Required: Appeal form, denial letter, additional clinical evidence

External Review (Illinois-Specific Advantages):

  • Automatic forwarding: Medical necessity denials automatically go to external review unless you opt out
  • Specialist reviewers: Must be actively practicing in the same specialty
  • Timeline: 4 months to request, 45 days for decision (expedited: 72 hours)
  • Cost: Free to consumers
  • Binding: Decisions are binding on Aetna with up to $50,000 penalties for non-compliance

Illinois External Review Process: File online at Illinois Department of Insurance or call 877-527-9431 for assistance.

Medical Necessity Letter Checklist

When preparing your medical necessity documentation, include:

Clinical Foundation:

  • ✓ Confirmed Type 1 Gaucher disease diagnosis with enzyme activity levels
  • ✓ Specific symptoms requiring treatment (organomegaly, cytopenias, bone disease)
  • ✓ Current lab values and imaging results
  • ✓ Functional impairment or quality of life impact

Treatment History:

  • ✓ Previous therapies tried and outcomes
  • ✓ Reasons for Elelyso failure or contraindication
  • ✓ Response to prior Cerezyme if applicable
  • ✓ Adverse events with alternative treatments

Evidence-Based Support:

  • ✓ FDA prescribing information for Cerezyme
  • ✓ Peer-reviewed studies supporting use
  • ✓ Professional society guidelines (if applicable)
  • ✓ Specialist recommendation letter

Monitoring Plan:

  • ✓ Proposed dosing regimen (2.5-60 units/kg as appropriate)
  • ✓ Infusion site and supervision arrangements
  • ✓ Follow-up schedule and outcome measures
  • ✓ Safety monitoring protocols

Cost-Saving Options

Manufacturer Support:

  • Sanofi Patient Support Program offers copay assistance and navigation services
  • Contact: Cerezyme.com for current programs

Foundation Assistance:

  • National Gaucher Foundation provides grants and advocacy support
  • Local rare disease organizations may offer additional resources

State Programs:

  • Illinois Medicaid covers Cerezyme with prior authorization
  • State pharmaceutical assistance programs (verify current eligibility)

When to Escalate

Illinois Department of Insurance:

  • Consumer assistance: 877-527-9431
  • File complaints for processing delays or unfair denials
  • Online complaint portal available

Illinois Attorney General Health Care Helpline:

  • 1-877-305-5145 for informal intervention with insurers
  • Can assist with complex appeal cases requiring additional advocacy

Federal Options:

  • CMS for Medicare Part D issues
  • Department of Labor for ERISA plans
  • State insurance commissioner complaints

Frequently Asked Questions

How long does Aetna CVS Health prior authorization take in Illinois? Standard requests: up to 72 hours. Urgent requests: 24-72 hours. Submit complete documentation to avoid delays.

What if Cerezyme is non-formulary on my plan? Request a formulary exception with medical necessity documentation. Include FDA approval evidence and specialist support.

Can I request an expedited appeal? Yes, if delay could jeopardize your health. Mark appeals "URGENT" and provide clinical justification for expedited review.

Does step therapy apply if I've been stable on Cerezyme? Generally no - stable patients face risk with switches. Document stability and potential risks of changing therapy.

What happens if my internal appeal is denied? In Illinois, medical necessity denials automatically go to external review unless you opt out. The external reviewer's decision is binding.

Can my primary care doctor prescribe Cerezyme? Aetna typically requires a specialist (hematologist or Gaucher expert) due to the complexity of treatment and infusion reaction management.

How do I prove medical necessity for Cerezyme vs. other ERTs? Document specific reasons why alternatives are inappropriate: adverse reactions, inadequate response, contraindications, or stability on current therapy.

What if I need Cerezyme immediately? File an expedited prior authorization and appeal simultaneously if needed. Illinois requires urgent decisions within 24-72 hours.

Navigating insurance coverage for rare disease treatments like Cerezyme can feel overwhelming, but you don't have to do it alone. Counterforce Health specializes in turning insurance denials into targeted, evidence-backed appeals. Our platform analyzes denial letters, identifies specific policy requirements, and drafts point-by-point rebuttals that align with your insurer's own rules. We help patients, clinicians, and specialty pharmacies get prescription drugs approved by providing the right clinical evidence, proper documentation, and strategic appeal approaches that insurance companies expect.

Illinois residents have particularly strong appeal rights, and with proper documentation and strategic approach, many Cerezyme denials can be successfully overturned. The key is understanding Aetna CVS Health's specific requirements, working with experienced specialists, and leveraging Illinois's robust external review process when needed.

Sources & Further Reading

This article provides educational information and should not be considered medical advice. Always consult with your healthcare provider regarding treatment decisions. For personalized assistance with insurance appeals and coverage issues, contact the Illinois Department of Insurance consumer assistance line at 877-527-9431.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.